Contraindicated (one)bortezomib will enhance the degree or result of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or average CYP2C19 inhibitors might enhance mavacamten systemic publicity, leading to heart failure resulting from systolic dysfunction. elvitegravir/cobicistat/emtricitabine/tenofovir DF will increase amounts of bortezomib by impactin... https://cg-80679135.blogrelation.com/32700364/the-smart-trick-of-anisperimus-that-no-one-is-discussing